I am a neurologist specialized in neurological rehabilitation and a neuroscientist with background in neurophysiology, neuroimaging and molecular neuroimaging. My main interest is translational neuropharmacology in neurological disorders without a proven treatment or in which we may be able to move beyond the current gold-standard to improve neurological outcomes. I am particularly interested in dopaminergic neurotransmission and drug development. My main approach involves the use of molecular neuroimaging and selected radiopharmaceuticals aiming at: 1- Finding new biomarkers for the disease of interest by selecting or creating a ligand that targets specific neurotransmitter systems believed to participate in the underlying neurological disorder; 2- Understanding the specific pharmacodynamics underneath the pathophysiology of the disease by manipulating the chosen ligand with acute pharmacological interventions competing with it. 3- Translational neuropharmacology from animals to human use. This clear potential value of a translational molecular neuroimaging strategy at the earliest stages of new drug development is my personal field of interest. The ultimate goal is to bring pharmacodynamics information up to Phase II clinical trials for future innovative neuropharmacological therapeutic interventions for convalescent patients from brain disorders. Due to my previous clinical expertise in the field of neurorehabilitation, my interests are tightly related but not restricted to the treatment of patients convalescent from brain diseases.